Contemporary use of clopidogrel in patients with coronary artery disease

Sahil A. Parikh, Joshua A. Beckman

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Antiplatelet agents have long served as the cornerstone of pharmacologic therapy to prevent atherothrombotic events. The thienopyridines have risen to prominence as both an alternative and adjunctive treatment to aspirin monotherapy. These agents prevent platelet aggregation by selectively and irreversibly blocking the platelet ADP P2Y12 receptor. In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease. We assess the use of clopidogrel following revascularization for coronary artery disease with percutaneous coronary intervention, particularly after deployment of drug-eluting stents. Finally, we address some aspects of clopidogrel resistance.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCurrent Cardiology Reports
Issue number4
StatePublished - Jul 2007
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Contemporary use of clopidogrel in patients with coronary artery disease'. Together they form a unique fingerprint.

Cite this